Concepedia

Elisabeth Buchdunger

EB

Statistics

Publications

54

Citations

20.1K

H-Index

42

Active since

1994

Affiliations

Novartis (Switzerland)(Current)

University of Helsinki

Helsinki University Hospital

Ludwig Cancer Research

Oregon Health & Science University

Elisabeth Buchdunger is an author at Novartis (Switzerland) specializing in pharmacology, tyrosine kinase inhibitors, and medicine.

Publications per year

1994–2020

54

Publications

54

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian Druker, Moshe Talpaz, Debra Resta et al. · New England Journal of Medicine · 2001 · 5.2K citations · Full text

, , +12

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Brian Druker, Shu Tamura, Elisabeth Buchdunger et al. · Nature Medicine · 1996 · 3.7K citations

, , +13

Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors

Elisabeth Buchdunger, Catherine L. Cioffi, Norman M. Law et al. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 1.3K citations

, , +15

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

Elisabeth Buchdunger, J. Zimmermann, Helmut Mett et al. · PubMed · 1996 · 1.1K citations

, , +17

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

J M Wood, Guido Bold, Elisabeth Buchdunger et al. · PubMed · 2000 · 847 citations

, , +16

1–5 of 54